Natick-based Boston Scientific is beginning clinical tests of a new catheter designed to treat a type of heart arrhythmia known as atrial flutter.
The trial plans to enroll up to 240 patients at 22 U.S. sites.
The company said atrial flutter affects nearly a million people in the U.S., causing heart palpitations, shortness of breath, fatigue, lightheadedness and fainting. It said the new product, the Blazer Open-Irrigated Catheter, could replace anti-arrhythmic drugs as a first-line approach for some patients.
